Showing results (11-20 of 70) with videos related to
Sort By:
Pageof 7
Gynecologic Oncology|September 24, 2004
Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancerD Scott McMeekin, Todd Tillmanns, Taimur Chaudry, et al.Gynecologic Oncology|October 31, 2008
Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group studyD Scott McMeekin, Joan L Walker, Ellen M Hartenbach, et al.Gynecologic Oncology|July 18, 2016
The pro-inflammatory effect of obesity on high grade serous ovarian cancerCamille C Gunderson, Kai Ding, Justin Dvorak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-PDon S Dizon, John A Blessing, D Scott McMeekin, et al.Gynecologic Oncology|June 25, 2003
A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancerD Scott McMeekin, Alan Gordon, Jeffrey Fowler, et al.Gynecologic Oncology|November 8, 2005
Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupCheryl A Brewer, John A Blessing, Robert A Nagourney, et al.Gynecologic Oncology|December 28, 2020
Phase II trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched, high-intermediate risk factors for recurrenceTara Castellano, I V John Maxwell, J Adam Walter, et al.Gynecologic Oncology|January 15, 2008
Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomesKathleen N Moore, Michael A Gold, D Scott McMeekin, et al.Gynecologic Oncology|June 14, 2011
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancerLisa M Landrum, Johnny Hyde, Robert S Mannel, et al.Cancer|August 26, 2010
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysisKathleen N Moore, Chunqiao Tian, D Scott McMeekin, et al.Pageof 7